Stocks and Investing Stocks and Investing
Wed, January 20, 2021
Tue, January 19, 2021

Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $251 on, Jan 19th, 2021


Published on 2024-10-27 15:17:06 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $249 to $251 on, Jan 19th, 2021.

Matthew has made no other calls on VRTX in the last 4 months.



There are 8 other peers that have a rating on VRTX. Out of the 8 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $257 on, Friday, October 30th, 2020


These are the ratings of the 7 analyists that currently disagree with Matthew


  • Brian Abrahams of "RBC Capital" Maintained at Buy and Held Target at $265 on, Tuesday, December 8th, 2020
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $288 on, Friday, November 20th, 2020
  • Vincent Chen of "Bernstein" Initiated at Buy and Held Target at $275 on, Friday, November 20th, 2020
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $285 on, Friday, October 30th, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $307 on, Friday, October 30th, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $277 on, Friday, October 30th, 2020
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020
Contributing Sources